Respiratory syncytial virus (RSV) is a significant contributor to infant mortality with limited prevention and treatment options. The fusion glycoprotein of RSV is thought as an ideal target for vaccine R&D, which exists in pre- and post-fusion forms. Due to their different performance in inducing neutralizing antibodies, confirming RSV F protein conformation is crucial throughout vaccine development and assessment. Our application note explores protocols and technical considerations for how to identifying conformational changes in the RSV protein to help ensure that your RSV F protein is structurally accurate.